Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.41 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
| ▸ | STK3 | Q13188 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18439072 | 0.85 | MAP2K1 (0.74) | MAP2K1NPC1RAB9AXDHALDH1A1 | |
| SCHEMBL18439955 | 0.85 | MAP2K1 (0.74) | MAP2K1NPC1RAB9AXDHALDH1A1 | |
| SCHEMBL4145521 | 0.84 | MAP2K1 (1.00) | MAP2K1NPC1RAB9AXDHALDH1A1 | |
| SCHEMBL10868011 | 0.81 | MAP2K1 (0.68) | MAP2K1NPC1RAB9AALDH1A1ALDH1A3 | |
| SCHEMBL18439066 | 0.81 | MAP2K1 (0.68) | MAP2K1NPC1RAB9AXDHALDH1A1 | |
| SCHEMBL18439808 | 0.81 | MAP2K1 (0.68) | MAP2K1NPC1RAB9AXDHALDH1A1 | |
| SCHEMBL18439068 | 0.81 | MAP2K1 (0.68) | MAP2K1NPC1RAB9AXDHALDH1A1 | |
| SCHEMBL10866639 | 0.80 | MAP2K1 (0.67) | MAP2K1NPC1RAB9AXDHALDH1A1 | |
| SCHEMBL18439076 | 0.80 | MAP2K1 (0.67) | MAP2K1NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL10867307 | 0.77 | MAP2K1 (0.62) | MAP2K1NPC1RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626115-B2 | Fused pyrimidinone and triazinone derivatives containing bridged nitrogen, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents | UNIVERSITE DE NANTES (FR) | 2020-04-21 | — | — | US | disclosed |
| US-20190002467-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES CONTAINING BRIDGED NITROGEN, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS | UNIVERSITE DE NANTES (FR) | 2019-01-03 | — | — | US | disclosed |
| EP-3328862-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS. | Universite de Nantes (FR) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017021178-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS. | UNIVERSITE DE NANTES (FR) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017020944-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS | UNIVERSITE DE NANTES (FR) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017020944-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS | UNIVERSITE DE NANTES (FR) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017021178-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS. | UNIVERSITE DE NANTES (FR) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626115-B2 | Fused pyrimidinone and triazinone derivatives containing bridged nitrogen, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents | DHFR, SAMHD1, TYMP | MAP2K1 980/4885NPC1 1385/4885RAB9A 2336/4885 |
| US-20190002467-A1 | NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES CONTAINING BRIDGED NITROGEN, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS | SAMHD1, DHFR, TYMP | MAP2K1 1232/4885NPC1 1252/4885RAB9A 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.